WO2001066121A1 - OLEORRESINA DE HYPERICUM PERFORATUM L., PROCEDIMIENTO DE OBTENCION Y_Usos - Google Patents
OLEORRESINA DE HYPERICUM PERFORATUM L., PROCEDIMIENTO DE OBTENCION Y_Usos Download PDFInfo
- Publication number
- WO2001066121A1 WO2001066121A1 PCT/ES2001/000080 ES0100080W WO0166121A1 WO 2001066121 A1 WO2001066121 A1 WO 2001066121A1 ES 0100080 W ES0100080 W ES 0100080W WO 0166121 A1 WO0166121 A1 WO 0166121A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oleoresin
- hypeπcum
- water
- perforatum
- obtaining
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention describes an oleoresin or pedic extract of Hype ⁇ cum perforatum L which contains hype ⁇ cina and enriched in hyperfonnas stable over time without the addition of stabilizers.
- the extract is obtained by extraction with solvents of low polarity and subsequent purification by reextraction with water-alkanols.
- the invention also relates to water-soluble gels whose active ingredient is Hypencum perforatum L oleoresin for use as a healing agent.
- Hype ⁇ cum perforatum L as a healing agent and in the treatment of burns has long been known for folk medicine.
- Hype ⁇ cum perforatum L hyperfo ⁇ nas and adhiperfo ⁇ nas acylfloroglucinoles stand out, also in the Hype ⁇ cum perforatum are the naptidiantrones hype ⁇ cma and pseudohipe ⁇ cina These compounds are responsible for the activity of the extracts in the treatment of wounds and scars, but these products are unstable when you try to obtain them in their pure state and decompose over time, by the action of light and heat
- European patent EP0854726 describes the obtaining of stabilized extracts of Hype ⁇ cum perforatum L by the addition of antioxidant preservatives such as ascorbic acid, cysteine and / or glutathione, the plant being extracted by organic solvents or alcohol-water mixtures.
- the galenic formulations described in the state of the art DE2406452 are ointments containing as active ingredients the fresh Hypericum leaves and as diluting fatty type excipients (olive oil, beeswax, fatty acid esters, etc.) , providing an ointment of lipophilic nature and insoluble in water.
- the extracts of Hypericum perforatum L. have shown different pharmacological activities, mainly as healing agents as mentioned above, but to date the activity of the extracts on the modulation of the extracellular matrix (ECM) of fibroblasts has not been described.
- ECM extracellular matrix
- the technical problem of the invention is to provide stabilized extracts of Hypericum perforatum L, without the addition of stable preservatives over time without losing their active components and that retain their pharmacological activity.
- the invention is surprisingly based on the stability of Hypericum perforatum L lipid extracts, which contain all their natural components: hyperforins and hyperkines, in a lipid-like matrix, these extracts being stable over time. time without the addition of preservatives Lipid extracts or oleorescence are obtained by extraction with solvents of low polarity capable of extracting the lipid components of the drug and subsequent purification by reextraction with water-alkanols
- the extracts have a content greater than 10% in hyperfo ⁇ nas and a content in hype ⁇ cinas greater than 0.5% in a lipid matrix that stabilizes the active ingredients of Hype ⁇ cum perforatum L
- the extracts have shown a dose-dependent activity in the regulation of the production of the components of the extracellular matrix In this way the possible toxicity of the product is avoided since the production of collagen and tenastma is inhibited at high doses and on the other hand prevents the formation of hypertrophic scars and keloids
- the extracts described can be used in pharmaceutical or galenic preparations such as water-soluble gels as healing agents that improve bioavailability, which prevent maceration in skin, which improve the application of the product against the formulations described by the state of the art based on excipients fatty or pophilic Likewise with the use of water-soluble gels, a better follow-up of the lesions can be carried out because it is a transparent gel
- the invention is based on the stability of the Hype ⁇ cum perforatum L extracts, characterized by the presence of hype ⁇ cma and hyperfo ⁇ nas in a matrix of lipid nature
- the extracts are obtained by extracting Hype ⁇ cum perforatum L first with a solvent of low polarity and subsequent reextraction with hot-water-alcohol mixtures, obtaining a fluid oleorescence with a hyperfo ⁇ na content greater than 10% and a hype ⁇ cine content greater than 0.5% Hype ⁇ cum perforatum L fluid oleoresins obtained by extractions with low polarity solvents and subsequent reextraction with low weight alkanol mixtures Molecular and hot water, they have been stable, without losing their hyperphobic content under the action of light and temperature.
- the hyperphobic content after a year of storage at 40 ° C exposed to light and at room temperature has shown a content in hyperio ⁇ nas of 15%
- the Hype ⁇ cum perforatum L is extracted at low temperature with solvents with a polarity of less than 0.6, the solvent to be used is not critical, and solvent mixtures can be used
- the plant is extracted in the proportion of one part of a drug for every 6 parts of solvent, by 24 hour maceration at a temperature less than or equal to 20 ° C, then it is filtered and the drug is re-extracted by maceration for 24 hours, so on until the extraction is depleted
- the extracts in liquid form are concentrated until obtaining a soft and fluid syrup by means of high vacuum and at a temperature below 40 ° C
- the soft liquid syrup is purified by dissolving in a mixture of alkanols-water and filtered, preferably using low molecular weight alcohols such as methanol, ethanol or isopropanol.
- the solution is made at 40-50 ° C and once filtered concentrated under reduced pressure to obtain a fluid oleoresin
- the oleoresins obtained have a high content in hyperfo ⁇ nas of 10-15% and a content in hype ⁇ cmas stable over time, determined by chromatographic or spectrophotomatic techniques.
- Additional steps can be added to the extraction process, such as selecting the starting raw materials with a hyperfo ⁇ na content greater than 2%, dehydration of the material materials at a temperature below 35 ° C, plant cogenization, etc.
- water-soluble gels are obtained that facilitate the release of oleoresin from Hype ⁇ cum perforatum L, of a fat-soluble nature, allowing diffusion between the structures of the corneal layer obtaining a greater bioavailability than in oil solutions
- These water-soluble gels contain diluents, emulsifying gelling moisturizers and preservatives
- the preservatives are dissolved in water and the Hype ⁇ cum perforatum L oleoresin is dissolved in the emulsifiers. On this mixture the preservatives dissolved in water are incorporated, subsequently incorporating the humectants and gelling agents slowly and slowly preventing occlusion of air
- water can be used as a diluent, g ce ⁇ na as g ce ⁇ lo palmitate humectant as a gelling agent, parabens as preservatives and PEG-40-hydrogenant Castor Oil Polorsorbate-20 and Octoxynol-1 1 as emulsifiers
- Hype ⁇ cum oleoresins regulate the production of extracellular matrix (ECM) components such as collagen and tenastma, but surprisingly this regulation is dose dependent
- Hype ⁇ cum perforatum L oleoresins at low concentrations increase production by 70% collagen synthesis in fibroblast cultures but at concentrations greater than 5 ⁇ g / ml collagen synthesis is inhibited, avoiding possible product toxicity and avoiding the formation of hypertrophic or keloid scars 5
- the production of tenascin decreases after the treatment of the fibroblasts with the Hype ⁇ cum oleoresin for 24 h at 37 ° C in a dose-dependent manner
- Example 1 Illustrates the procedure for obtaining the oleoresins of Hypericum perforatum L.
- Example 2 Illustrates the stability of the extracts.
- the extracts A, B, C are oleoresres of Hype ⁇ cum perforatum L obtained according to the invention and extract D, an extract of Hype ⁇ cum perforatum L obtained by extraction with ethanol, water (50 50)
- the oleoresins of Hype ⁇ cum perforatum L obtained according to the invention are stable and the hyperfo ⁇ nas content does not decrease with temperature or light
- Example 3 Illustrates the regulation of the production of extracellular membrane components.
- the fibroblasts were obtained from the surgical material. Skin samples were pre-incubated for 2 hours at 40 ° C in RPMI 1640 with 2% penicillin / espreptomycin. Fatty tissues were removed and the skin was cut into small pieces and fixed. in culture discs moistened with calf serum (FCS) The skin pieces were incubated at 37 ° C in a CO2 atmosphere in RPMI with 10% FCS and 1% penicillin / streptonicin The culture medium was changed 2 times per week The fibroblast culture was t ⁇ psinized (t ⁇ psin / EDTA 0.0% / 0.02%) and subcultured. Cells from 4th to 14th were used.
- FCS calf serum
- the contents of the plates were transferred to polypropylene tubes in which 800 ⁇ l of 0.5M acetic acid was added which contained a soluble neutral salt of rat skin collagen (200 ⁇ l) as a diluent
- the tubes were centrifuged at 4000 g for 20 minutes
- the collagen was precipitated from the supernatant by the addition of 250 ⁇ l of NaCI in acetic acid (25%) pro tube
- the tubes were centrifuged at 4,000 g for 30 minutes the precipitates were redissolved in 0.15M 0.15M NaCl in 0.05M of t ⁇ s-HCI, pH 7.5
- the collagen was precipitated by the addition of 2 ml of 4.5M NaCl in the same buffer
- the tubes were centrifuged at 4000 g for 30 minutes
- the supernatant was discarded and the collagen precipitates were washed in 2 ml of 2% ethanol and centrifuged at 4000 g for 30 minutes
- each precipitate was dissolved in 250 ⁇
- the fibroblasts were cultured in microplates with a density of 20,000 cells per plate with RPMI medium without FCS After 24 hours at 37 ° C in a 5% CO2 atmosphere the culture medium was changed. The cells were incubated 48 hours more at 37 ° C with different concentrations of oleoresin The cells were washed 3 times with PBS with 1% BSA and 0.1% Tween 20 The cells were fixed with a methanol / acetone solution (1 1) and washed 3 times as described above and incubated with a monoclone antitenascin antibody! for 1 hour at 37 ° C. After washing, the cells were incubated with a goat anti-mouse monoclonal antibody with alkaline phosphatase.
- the cells were washed 3 times and incubated with p-nitrophenyl phosphate (1 mg / ml) for 15 minutes.
- the microplates were centrifuged at 200 g and 100 ⁇ l of the supernatant transferred to a new microplate.
- the plates were read in an ELISA reader at 405 nm.
- Example 4 Illustrates the results obtained with the water-soluble oleoresin gel of Hypericum perforatum L. in the healing agent.
- Product B - Water-soluble gel with a 0.5% oleoresin content of Hypericum perforatum L.
- Group 2 Patients with dermatological pathology that requires surgical excision and closure by suture, the wounds are treated clinically
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001564773A JP2003525904A (ja) | 2000-03-06 | 2001-03-02 | 西洋オトギリソウ樹脂油、それを得るための方法およびそれの使用 |
CA002372931A CA2372931A1 (en) | 2000-03-06 | 2001-03-02 | Oleoresin of hypericum perforatum l., method for obtaining said oleoresin and the use thereof |
US09/959,647 US6699512B2 (en) | 2000-03-06 | 2001-03-02 | Hypericum perforatum l. oleoresin, procedure for obtaining it and uses of it |
AU37446/01A AU3744601A (en) | 2000-03-06 | 2001-03-02 | Oleoresin of hypericum perforatum L., method for obtaining said oleoresin and the use thereof |
EP01909839A EP1175908A1 (en) | 2000-03-06 | 2001-03-02 | Oleoresin of hypericum perforatum l., method for obtaining said oleoresin and the use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP200000586 | 2000-03-06 | ||
ES200000586A ES2159270B1 (es) | 2000-03-06 | 2000-03-06 | Oleorresina de hypericum perforatum l., procedimiento de obtencion y usos. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001066121A1 true WO2001066121A1 (es) | 2001-09-13 |
Family
ID=8492663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2001/000080 WO2001066121A1 (es) | 2000-03-06 | 2001-03-02 | OLEORRESINA DE HYPERICUM PERFORATUM L., PROCEDIMIENTO DE OBTENCION Y_Usos |
Country Status (7)
Country | Link |
---|---|
US (1) | US6699512B2 (es) |
EP (1) | EP1175908A1 (es) |
JP (1) | JP2003525904A (es) |
AU (1) | AU3744601A (es) |
CA (1) | CA2372931A1 (es) |
ES (1) | ES2159270B1 (es) |
WO (1) | WO2001066121A1 (es) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006061446A1 (es) * | 2004-12-07 | 2006-06-15 | Asac Pharmaceutical International Aie | Composiciones farmaceuticas |
ES2308940A1 (es) * | 2004-12-07 | 2008-12-01 | Asac Pharmaceutical International Aie | Composiciones farmaceuticas. |
WO2010133707A1 (es) * | 2009-05-18 | 2010-11-25 | Asac Compañía De Biotecnología E Investigación Sa | Soluciones de hiperforinas estabilizadas para administración oral |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITRM20040393A1 (it) * | 2004-08-03 | 2004-11-03 | Enea Ente Nuove Tec | Composizione naturale con proprieta' cicatrizzante, repellente e biocida per il trattamento e la risoluzione delle lesioni esterne. |
EP1640041A3 (de) * | 2004-09-24 | 2006-05-24 | Henkel Kommanditgesellschaft auf Aktien | Kosmetische und dermatologische Zusammensetzungen zur Behandlung reifer oder lichtgeschädigter Haut |
US20060115555A1 (en) * | 2004-12-01 | 2006-06-01 | Foulger Sidney W | Nutritional supplements containing xanthone extracts |
US20060115556A1 (en) * | 2004-12-01 | 2006-06-01 | Foulger Sidney W | Nutritional supplement drink containing xanthone extracts |
FR2884144B1 (fr) * | 2005-04-07 | 2008-04-11 | Eric Peltier | Combinaison d'un fixateur histologique ou cytologique, et d'un ou plusieurs composes photoactivables de la famille des quinones, en particulier l'hypericine, l'hypocrelline a et l'hypocrelline b. |
WO2006135965A1 (en) * | 2005-06-20 | 2006-12-28 | Dynamiclear Pty Ltd | Composition for treating skin lesions |
US20110064826A1 (en) * | 2005-06-20 | 2011-03-17 | John Spurge | Composition for treating skin lesions |
DE102005032352A1 (de) * | 2005-07-08 | 2007-01-11 | Aquanova German Solubilisate Technologies (Agt) Gmbh | Solubilisate pfanzlicher Wirkstoffe sowie Verfahren zur Herstellung der Solubilisate |
US9421161B2 (en) | 2012-04-10 | 2016-08-23 | Robert Thomas van Aller | Herbal composition and a method of making thereof |
RU2568912C1 (ru) * | 2014-12-12 | 2015-11-20 | Федеральное государственное образовательное учреждение высшего профессионального образования "Кубанский государственный университет" (ФГБОУ ВПО "КубГУ") | СПОСОБ ЭКСТРАКЦИИ БИОЛОГИЧЕСКИ АКТИВНЫХ ВЕЩЕСТВ ИЗ ЗВЕРОБОЯ ПРОДЫРЯВЛЕННОГО (Hypericum perforatum L.) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3935772C2 (es) * | 1989-10-24 | 1993-08-05 | Steigerwald Arzneimittelwerk Gmbh, 6100 Darmstadt, De | |
WO1999064027A1 (en) * | 1998-06-10 | 1999-12-16 | Indena S.P.A. | Extracts of hypericum perforatum and formulations containing them |
EP0965348A1 (de) * | 1998-04-22 | 1999-12-22 | Plantamed Arzneimittel GmbH | Verfahren zur schonenden Gewinnung von Extraktfraktionen aus Hypericum perforatum L., diese enthaltende pharmazeutische Zubereitungen und Verwendung derselben |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19646977A1 (de) * | 1995-09-29 | 1998-01-15 | Schwabe Willmar Gmbh & Co | Stabiler Extrakt aus Hypericum perforatum L., Verfahren zu seiner Herstellung und pharmazeutische Zubereitungen |
US6238671B1 (en) * | 1998-04-22 | 2001-05-29 | Bionorica Arzneimittel Gmbh | Process for the gentle recovery of extract fractions from hypericum, pharmaceutical preparations containing the same and their use |
US6291241B1 (en) * | 1999-03-29 | 2001-09-18 | Trevor Percival Castor | Methods for making Hypericum fractions and St. John's Wort products |
US6224906B1 (en) * | 1999-08-31 | 2001-05-01 | Natreon Inc. | St. John's wort composition |
-
2000
- 2000-03-06 ES ES200000586A patent/ES2159270B1/es not_active Expired - Fee Related
-
2001
- 2001-03-02 JP JP2001564773A patent/JP2003525904A/ja not_active Withdrawn
- 2001-03-02 WO PCT/ES2001/000080 patent/WO2001066121A1/es active Application Filing
- 2001-03-02 CA CA002372931A patent/CA2372931A1/en not_active Abandoned
- 2001-03-02 AU AU37446/01A patent/AU3744601A/en not_active Abandoned
- 2001-03-02 US US09/959,647 patent/US6699512B2/en not_active Expired - Fee Related
- 2001-03-02 EP EP01909839A patent/EP1175908A1/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3935772C2 (es) * | 1989-10-24 | 1993-08-05 | Steigerwald Arzneimittelwerk Gmbh, 6100 Darmstadt, De | |
EP0965348A1 (de) * | 1998-04-22 | 1999-12-22 | Plantamed Arzneimittel GmbH | Verfahren zur schonenden Gewinnung von Extraktfraktionen aus Hypericum perforatum L., diese enthaltende pharmazeutische Zubereitungen und Verwendung derselben |
WO1999064027A1 (en) * | 1998-06-10 | 1999-12-16 | Indena S.P.A. | Extracts of hypericum perforatum and formulations containing them |
Non-Patent Citations (3)
Title |
---|
HOELZL J. ET AL.: "Comparison of the hypericin and peroxide concentration of commercial and self-produced oleum hyperici and it effects on serotonin uptake", PLANTA MEDICA, vol. 55, no. 7, 1989, pages 601 - 602, XP002905652 * |
MAISENBACHER P. ET AL.: "Analysis and stability of hyperici oleum", PLANTA MEDICA, vol. 58, no. 4, 1992, pages 351 - 354, XP000964768 * |
ORTH H.C.J. ET AL.: "Stability and stabilization of hyperforin", DRUGS MADE IN GERMANY, vol. 42, no. 4, 1999, pages 110 - 113, XP002905653 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006061446A1 (es) * | 2004-12-07 | 2006-06-15 | Asac Pharmaceutical International Aie | Composiciones farmaceuticas |
ES2308940A1 (es) * | 2004-12-07 | 2008-12-01 | Asac Pharmaceutical International Aie | Composiciones farmaceuticas. |
WO2010133707A1 (es) * | 2009-05-18 | 2010-11-25 | Asac Compañía De Biotecnología E Investigación Sa | Soluciones de hiperforinas estabilizadas para administración oral |
Also Published As
Publication number | Publication date |
---|---|
CA2372931A1 (en) | 2001-09-13 |
EP1175908A1 (en) | 2002-01-30 |
US20020197337A1 (en) | 2002-12-26 |
ES2159270A1 (es) | 2001-09-16 |
ES2159270B1 (es) | 2002-04-01 |
JP2003525904A (ja) | 2003-09-02 |
US6699512B2 (en) | 2004-03-02 |
AU3744601A (en) | 2001-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2490715T3 (es) | Composiciones que comprenden células fetales no diferenciadas para el tratamiento de trastornos cutáneos | |
ES2383599T3 (es) | Composición farmacéutica para tratamiento de enfermedades cardiovasculares y cerebrovasculares | |
ES2270894T3 (es) | Utilizacion de un extracto de al menos un vegetal de genero vaccinium como agente anti glicacion. | |
ES2294697T3 (es) | Composiciones farmaceuticas a base de barba de capuchino (usnea barbata) y hierba de san juan (hypericum perforatum), asi como su uso. | |
WO2001066121A1 (es) | OLEORRESINA DE HYPERICUM PERFORATUM L., PROCEDIMIENTO DE OBTENCION Y_Usos | |
KR20030009454A (ko) | 진세노사이드Rb1으로 된 피부조직 재생촉진제 | |
US20130071501A1 (en) | Extract of stewartia koreana and use thereof | |
BR112015030543B1 (pt) | Preparação para aplicação tópica para o tratamento da pele e infecções da mucosa | |
JP2005306870A (ja) | 皮膚保湿用化粧料組成物 | |
KR20180119941A (ko) | 쉬나무 추출물을 유효성분으로 하는 창상 치유용 약학 조성물 | |
EP0109993B1 (en) | Method for extracting propolis and water soluble dry propolis powder obtained thereby and cosmetic and pharmaceutical preparations containing same | |
EP2344173A1 (en) | New synergic association for the treatment of deep skin or mucosa injuries | |
US20110002968A1 (en) | Cosmetic or dermatological composition containing an orchid extract, and cosmetic care method using said composition | |
US20090238848A1 (en) | Use of an Extract of the Orchid Vanda Coerulea as a Skin Hydrating Agent | |
ES2909243T3 (es) | Extracto de salvia haenkei como un agente activo en procesos de reepitelización y cicatrización de tejidos | |
KR20170098145A (ko) | 피뿌리풀 추출물 또는 그의 분획물을 포함하는 화장 조성물 및 그의 용도 | |
JPS6267028A (ja) | 肌荒れ防止剤 | |
KR101679391B1 (ko) | 피뿌리풀 추출물 또는 그의 분획물을 포함하는 상처를 치료하기 위한 조성물 및 개체의 상처를 치료하는 방법 | |
KR20040041912A (ko) | 동충하초 추출물을 유효성분으로 포함하는 항염 조성물 | |
Muhamad Ibrahim et al. | Swertiamarin ointment: a traditional approach in cutaneous wound healing | |
JP2002526395A (ja) | 化粧品あるいは皮膚科製品におけるボルド抽出物の使用 | |
JPH05194214A (ja) | 創傷治癒促進剤 | |
TWI817071B (zh) | 一種可應用於皮膚外用投予且提升活性物質效能的細胞穿透胜肽-活性物組合製劑 | |
JPH09315938A (ja) | 美白用化粧料組成物 | |
CA1168403A (en) | Method for extracting propolis and water soluble dry propolis powder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
ENP | Entry into the national phase |
Ref document number: 2372931 Country of ref document: CA Ref country code: CA Ref document number: 2372931 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 564773 Kind code of ref document: A Format of ref document f/p: F |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001909839 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 37446/01 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2001909839 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09959647 Country of ref document: US |